Signal vs Noise: Uterine Fibroids and Menopause Hormone Therapy

Uterine fibroids sit at the center of one of the noisiest decision-making spaces in menopause care. They are common, visible, structurally tangible—and yet, in most patients, clinically irrelevant. When menopause symptoms, abnormal bleeding, imaging findings, and hormone therapy intersect, it becomes easy to mistake coincidence for causation. Our clinical task is not to eliminate uncertainty, but to correctly identify which signals actually warrant a change in care.

More than half of patients entering menopause have uterine fibroids, and many are already using—or are candidates for—menopause hormone therapy without knowing those fibroids exist. The presence of fibroids alone does not predict symptoms, does not reliably explain bleeding, and does not automatically alter the risk–benefit profile of hormone therapy. Treating fibroids as a contraindication to MHT misunderstands both the epidemiology and the evidence.

One of the most common sources of noise is abnormal uterine bleeding. Bleeding is the most frequent side effect of menopause hormone therapy, particularly in the first three to six months of treatment. Fibroids are also commonly identified when patients are evaluated for bleeding. When these two facts collide, fibroids are often blamed—despite having been present long before therapy was initiated. In nearly half of abnormal uterine bleeding cases, fibroids coexist with another diagnosis, such as adenomyosis or perimenopausal endometrial instability. The fibroid is visible; the hormonal transition is not. Visibility is not causality.

We deliberately avoid binary thinking in this space. Fibroids are hormonally responsive, not hormonally driven. They exhibit higher estrogen and progesterone receptor density, but they are not caused by excess estrogen, nor does physiologic-dose hormone therapy reliably induce clinically meaningful growth. Across the available literature, true clinically relevant fibroid growth—generally defined as a >25% increase in volume—is uncommon. When growth does occur, it is most often small, transient, and not progressive beyond the first six months of therapy.

Importantly, symptom change does not reliably track with fibroid size. Fibroids may shrink during menopause, remain stable, or behave heterogeneously within the same individual. A decrease in size does not guarantee symptom improvement, and a small increase in size does not necessarily explain bleeding. Anchoring clinical decisions to imaging changes alone amplifies noise rather than clarifying signal.

Signal emerges when changes are sustained, progressive, and clinically meaningful. From a practical standpoint, we consider three markers that warrant reassessment:

• A sustained increase in bleeding beyond the expected three- to six-month adjustment window

• New or worsening bulk symptoms

• Documented fibroid growth exceeding thresholds used in research contexts

Absent these signals, early bleeding changes or incidental imaging findings do not justify discontinuation of hormone therapy.

Another source of noise comes from misapplied logic. The observation that fibroids regress under profound hormonal suppression (such as GnRH agonist therapy) has sometimes been used to argue against menopause hormone therapy. This reasoning fails to account for dose, context, and intent. Chemically inducing menopause is not equivalent to physiologic hormone replacement. The absence of regression with add-back therapy does not imply harm; it reflects a different therapeutic goal.

We also recognize that not all patients belong to the same category. Patients with large, symptomatic, or previously treated fibroids represent a different clinical population than those with small, incidental findings. In these cases, non-hormonal strategies or co-management may be appropriate. But extrapolating these decisions to all patients with fibroids collapses nuance and increases fear-driven care.

Ultimately, managing fibroids in the context of menopause hormone therapy requires tolerance for trade-offs. No intervention is free of side effects, and no outcome is perfectly predictable. Our role is to help patients understand which changes are expected, which warrant patience, and which truly require action. When clinicians can confidently separate signal from noise, patients are less likely to abandon effective care based on findings that were never clinically relevant in the first place.

This is not permissive care. It is precise care—rooted in prevalence, trajectory, and proportional response rather than reaction to incidental findings.

These essays reflect how we approach complex clinical decision-making. Inside The Confident Clinician, members have access to the full set of clinical orientations, condition-specific at-a-glance guidelines, and structured frameworks that show how to apply this thinking in practice. Together, they support clearer reasoning, stronger boundaries, and more confident care in uncertain clinical situations.